Last reviewed · How we verify
xylometazoline HCL 0.05% — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
xylometazoline HCL 0.05% (xylometazoline HCL 0.05%) — Schneider Children's Medical Center, Israel.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| xylometazoline HCL 0.05% TARGET | xylometazoline HCL 0.05% | Schneider Children's Medical Center, Israel | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- xylometazoline HCL 0.05% CI watch — RSS
- xylometazoline HCL 0.05% CI watch — Atom
- xylometazoline HCL 0.05% CI watch — JSON
- xylometazoline HCL 0.05% alone — RSS
Cite this brief
Drug Landscape (2026). xylometazoline HCL 0.05% — Competitive Intelligence Brief. https://druglandscape.com/ci/xylometazoline-hcl-0-05. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab